42. The method of claim 41 wherein said radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

REMARKS

Entry of the foregoing amendments prior to examination is respectfully requested. By the present amendments, claims 23-42 are presented which further limit the existing claims by providing that the administered chimeric anti-CD20 antibody has a variable heavy or light sequence corresponding to C2B8 (as recited in SEQ ID NO: 11 or 7 respectively) or provide for the administration of a chimeric anti-CD20 antibody having the capability to substantially totally deplete B cells when administered at a dosage of 0.4 mg/kg body weight within about 24 hours post-infusion, alone or in combination with a radiolabeled anti-CD20 antibody. Support for claims of this scope e.g., may be found at page 12, line 26, page 13 line 5, and numerous other places in the specification that refer to chimeric anti-CD20 antibodies generically (not just C2B8).

With respect to the recited dosage that the chimeric antibody effects substantially total B cell depletion within 24 hours post-infusion, this finds literal support at page 15, line 9, page 15, lines 21-25, page 16 lines 10-15, and the data in Table 1 and Table 2 which exemplify dosages of 0.4 mg/kg, and which are stated to result in nearly completion (97-99%) B cell depletion at said dosage.

Therefore, Applicants submit that the subject claims find literal written description support in the as-filed application.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: _____
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2200
(703) 905-2500 Facsimile

Date: